Jazz Pharmaceuticals’ dordaviprone, brand name Modeyso, is now the first FDA-approved therapy for recurrent H3 K27M-mutant diffuse midline glioma. The drug came from Jazz’s $935 million acquisition of Chimerix earlier this year.
The post Rare and Aggressive Brain Cancer Affecting Children Gets Its First FDA-Approved Drug appeared first on MedCity News.
